NASDAQ:MYL - Mylan Stock Price, Price Target & More

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan NV (NASDAQ:MYL) released its earnings results on Wednesday, May, 9th. The company reported $0.96 earnings per share for the quarter, missing the consensus estimate of $0.99 by $0.03. The business had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.74 billion. Mylan had a return on equity of 18.56% and a net margin of 6.04%. The firm's revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.93 earnings per share. View Mylan's Earnings History.

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Mylan.

Mylan issued an update on its FY18 earnings guidance on Wednesday, May, 9th. The company provided EPS guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.37. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.

19 Wall Street analysts have issued 12-month price objectives for Mylan's stock. Their forecasts range from $29.39 to $59.00. On average, they expect Mylan's share price to reach $46.7047 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View Analyst Ratings for Mylan.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Mylan saw a decrease in short interest in June. As of June 29th, there was short interest totalling 11,394,932 shares, a decrease of 33.0% from the June 15th total of 17,000,496 shares. Based on an average trading volume of 3,875,140 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.3% of the shares of the company are short sold. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS) and Merck KGaA (MKGAF).

Press coverage about MYL stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Mylan earned a news sentiment score of 0.14 on Accern's scale. They also assigned news coverage about the company an impact score of 45.86 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Mylan's stock is owned by a number of of retail and institutional investors. Top institutional investors include Hexavest Inc. (0.28%), Retirement Systems of Alabama (0.08%), Assenagon Asset Management S.A. (0.07%), Bank of Montreal Can (0.06%), Kirr Marbach & Co. LLC IN (0.04%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, LS Investment Advisors LLC, Hartford Investment Management Co., Nisa Investment Advisors LLC, Gateway Investment Advisers LLC and Kirr Marbach & Co. LLC IN. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

MYL stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Retirement Systems of Alabama, Highland Capital Management LLC, Clinton Group Inc., Fox Run Management L.L.C., Jabodon PT Co., Fjarde AP Fonden Fourth Swedish National Pension Fund and Cornerstone Wealth Management LLC. View Insider Buying and Selling for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $35.57.

Mylan has a market capitalization of $18.31 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]